Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer

Annals of Oncology

Volumn 13, Issue 4, 2002, Pages 546-552

  Venturini, M ^a   Del Mastro, L ^a   Garrone, O ^b   Angiolini, C ^a   Merlano, M ^b   Bergaglio, M ^a   Tolino, G ^a   Lambiase, A ^c   Baldini, A ^c   Canavese, G ^a   Rosso, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c ROCHE MILANO RICERCHE   (Italy)

Author keywords

Advanced breast cancer; Capecitabine; Docetaxel; Epirubicin; Phase I

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; INFECTION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0036236447     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf056     Document Type: Article

References (33)

1. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990
2. Breast cancer: Epidemiology, risk factors, screening
3. Cancer statistics, 1996
4. Current management of metastatic breast cancer
5. Salvage chemotherapy of breast cancer
6. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
7. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
8. Developments in chemotherapy of breast cancer
9. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
10. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
11. Capecitabine; a review of its clinical pharmacokinetics
12. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
13. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
14. A multicenter phase II trial of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer
15. Capecitabine: An active and well tolerated treatment option for patients with metastatic breast cancer recurring after taxane-containing chemotherapy. Results of a multicenter phase II trial
16. Capecitabine (Xeloda) as a treatment after failure to taxanes for metastatic breast cancer
17. Capecitabine as an oral chemotherapeutic agent in the treatment of refractory metastatic breast carcinoma (MBC)
18. A randomised, phase II study of Xeloda® (capecitabine) versus paclitaxel in breast cancer patients failing previous anthracycline therapy
19. A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged ≥55 years
20. Results of a large phase III trial of Xeloda/Taxotere® combination therapy vs Taxotere® monotherapy in metastatic breast cancer (MBC) patients
21. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
22. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC
23. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
24. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
25. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
26. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group
27. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer
28. Docetaxel in combination with epirubicin as first-line chemotherapy of metastatic breast cancer: Final results
29. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
30. Phase I study of docetaxel in combination with epirubicin as first line chemotherapy in metastatic breast cancer
31. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
32. Escalating doses of docetaxel and epirubicin as first-line therapy for metastatic breast cancer. A phase I/II study of the National Institute of Canada-Clinical Trials Group